-+ 0.00%
-+ 0.00%
-+ 0.00%

Compugen Q3 net loss narrows 17% to USD 5.8 million; Q3 revenues more than double to USD 3.82 million

PUBT·11/09/2026 12:05:09
Listen to the news
Compugen Q3 net loss narrows 17% to USD 5.8 million; Q3 revenues more than double to USD 3.82 million
  • Compugen’s third-quarter 2026 net loss narrowed 17% year over year to $5.8 million.
  • Revenues more than doubled year over year to $3.82 million.
  • Cash and cash-related balances totaled $117.5 million at September 30, with funding expected into 2029.
  • MAIA-ovarian completed enrollment, with COM701 results expected by the end of the first quarter of 2027.
  • AstraZeneca’s Phase 3 ARTEMIDE-Biliary01 high-level results for rilvegostomig are anticipated in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compugen Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611090700PR_NEWS_USPR_____LN92078) on November 09, 2026, and is solely responsible for the information contained therein.